Lansoprazole belongs to a class of antisecretory
  compounds,that do not exhibit anticholinergic or
  histamin H2-receptor antagonist properties ,but that 
 suppress gastric acid secretion that acts by specific 
 inhibition of the H+/K+-ATPase enzyme system.
- Lansoprazole may be useful in patients failing on a 
 histamine H2-receptor antagonist (Cimetidine,
  Ranitidine, Famotidine or Nizatidine).
- Absorption of lansoprazole begins only after the pellets 
 leave the stomach. Absorption is rapid, with peak plasma
  concentrations achieved about 1.5 hours after a dose by 
 mouth; bioavailability is reported to be 80% or more even 
 with the first dose.
- lansoprazole is extensively metabolized in the liver and
 excreted primarily in faces via  bile,only about 15 to
 30% of a dose is excreted in urine the plasma elimination 
 half-life is around 1.4 to 2 hours but the duration of action
  is much longer . 

- Each capsule of LANZOL® 30 contains:
     Lansoprazole (as enteric coated pellets)    30 mg
- Each capsule of LANZOL® 15 contains: 
     Lansoprazole (as enteric coated pellets)    15 mg

- Hypersensitivity to lansoprazole. 

- Antacids and sucralfate may reduce the bioavailability of
   LANZOL® , and should not be taken within 1 hour of a
  dose of LANZOL® . 
- Lansoprazole is thought to be a weak inducer of hepatic 
 cytochrome P450, and may affect the pharmacokinetics of 
 the drugs which are metabolized by this system. 
- LANZOL® may interferes with the absorption of drugs
  where gastric pH is important determinant of bioavailability, 
 (e.g. Ketoconazole, Iron salts, Ampicillin esters, and 

- LANZOL® should not be administered during pregnancy
  and lactation unless strictly indicated according to the 
 physician recommendations.

- LANZOL® has been well tolerated in both short-term and
  long-term treatment. 
- The most commonly reported possibly or probably 
 treatment-related a dverse event during maintenance therapy 
 was diarrhea. 

- Symptomatic response to therapy with LANZOL® does 
 not preclude the presence of gastric malignancy. 
- Dosage should be reduced in hepatic impairment. 

- LANZOL® Plastic jar of 14 capsules with a desiccant .
- LANZOL® Pack  of 10  strips each strips containe  
10 capsules.

Store in a dry place below 30 °C, protected from light and